Scandinavian startups on to the European Health Catapult finals

The result from the European Health Catapult semifinals for startups in the Biotech, MedTech and Digital Health categories are here, with a favourable outcome for team Scandinavia.

European Health Catapult (EHC) is a training programme and competition that boosts the development of top notch European health start-ups in Biotech, Medtech and Digital Health
through exposure to leading experts and international investors.

The programme is organized by EIT Health with the support of the Health Axis Europe.

Biotech Category:  Swedish company CARTANA AB from Karolinska Institute, represented by CEO Malte Kühnemund, was 1 out of 7 European startups that was selected in Delft,  for the finals that takes place in Paris in December.


MedTech Category: Estonian company IPDx, led by Christoff Neuman from Tartu University managed to secure a place in the  MedTech finals in San Sebastian together with 6 other startups.


Digital health Category: Two Scandinavian startups out of a total of seven startups, secured a spot in London for the final. Estonian Triumf Health and Swedish Alex Health AB.

In total out of the 5 Scandinavian companies that participated in the 3 semifinals, 4 was selected for the finals. We are proud to have such a strong Scandinavian presence in the final – fingers crossed and we wish all finalist good luck at EIT Health Summit in Paris in December.

CARTANA is a Biotech company within Research & Development (R&D), biomarker discovery and treatment validation with a patented In Situ Sequencing (ISS) technology, which is based on 20+ years of development by Prof Mats Nilsson (SciLifelab, Stockholm, Sweden).  CARTANA is now finishing the development of ISS reagent kits with patented technology and will launch its products for the Neuro- and Cancer research market in Q1 2020. To achieve the conversion to the product business model, CARTANA raises capital for product launch, marketing and sales, targeting major Core facilities, Pharma & Biotech companies, as well as data-mining Health tech companies globally.


IPDx – Decoding antibody Signatures

IPDx has developed a technology platform to unlock billions of antibodies to perform better diagnostics. With their discovery platform, IPDx identifies antibody signatures to develop into diagnostic kits and partners with pharma for development collaborations. They use partners with established sales channels to get their kits to the market. Current assets in development include tests for Breast and liver cancer, rheumatoid arthritis, and endometriosis. They are raising a Series A investment to get first sales of diagnostic tests and automate their discovery platform.

Triumf Health – behavioral therapeutics for pediatric patients

Personalised approach to improve patient outcomes & empower ill children by deli- vering behavioral therapeutics through a mobile game. Their multi-site pilot study showed that the game was positively perceived by pediatric cancer patients, resulting in high usability & acceptability evaluations. Furthermore, the findings indicated improvement in psychological well-being & quality of life. They are now starting RCTs among various disease groups in Finland, Estonia & Singapore. Importantly, the big data from the game is analyzed for the care team; their visual dashboard helps with treatment monitoring, improves medical visit effectiveness & communication. Their seed funding round is open.

Alex – empowering people to regain control

Today, 1 billion people are suffering from smoking addiction. 70% want to quit, but only 3% succeed without support. Alex is an AI companion that empowers people to regain control over their unwanted habits and mental health – starting with smoking cessation. Alex aspire to remove the boundaries of getting professional help when quitting unwanted habits, like smoking, overeating and stress. With artificial intelligence (AI) and cognitive behavioral therapy (CBT), we provide world-class support through your phone. Alex combats addiction at its core, leading to persistent change and less relapses.